share_log

Jefferies Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $14

Jefferies Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $14

杰富瑞维持对Foghorn Therapeutics的买入评级,降低目标价至14美元。
Benzinga ·  2024/12/17 03:09  · 评级/大行评级

Jefferies analyst Kelly Shi maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $18 to $14.

杰富瑞分析师Kelly Shi维持对Foghorn Therapeutics(纳斯达克:FHTX)的买入评级,并将目标价从18美元下调至14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发